Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Beatriz Morancho"'
Autor:
Adrián Sanz-Moreno, Sonia Palomeras, Kim Pedersen, Beatriz Morancho, Tomas Pascual, Patricia Galván, Sandra Benítez, Jorge Gomez-Miragaya, Marina Ciscar, Maria Jimenez, Sonia Pernas, Anna Petit, María Teresa Soler-Monsó, Gemma Viñas, Mansour Alsaleem, Emad A. Rakha, Andrew R. Green, Patricia G. Santamaria, Celine Mulder, Simone Lemeer, Joaquin Arribas, Aleix Prat, Teresa Puig, Eva Gonzalez-Suarez
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-18 (2021)
Abstract Background Around 15–20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. Despite the successful development of anti-HER2 drugs, intrinsic and acquired resistance represents a major
Externí odkaz:
https://doaj.org/article/30beb90cbbc444768fc569001a4484a0
Autor:
Rocio Vicario, Vicente Peg, Beatriz Morancho, Mariano Zacarias-Fluck, Junjie Zhang, Águeda Martínez-Barriocanal, Alexandra Navarro Jiménez, Claudia Aura, Octavio Burgues, Ana Lluch, Javier Cortés, Paolo Nuciforo, Isabel T Rubio, Elisabetta Marangoni, James Deeds, Markus Boehm, Robert Schlegel, Josep Tabernero, Rebecca Mosher, Joaquín Arribas
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0129876 (2015)
A chromosomal region that includes the gene encoding HER2, a receptor tyrosine kinase (RTK), is amplified in 20% of breast cancers. Although these tumors tend to respond to drugs directed against HER2, they frequently become resistant and resume thei
Externí odkaz:
https://doaj.org/article/b8f0cd35f328483ca3ba72a0f0e5b491
Autor:
Joan Albanell, Ana Rovira, Atanasio Pandiella, Federico Rojo, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles, Mohammad A. Sabbaghi, Elena Gavilán, Sandra Zazo, Francisco Javier Sánchez-Martín, Beatriz Morancho, Cristina Guardia, Mengjuan Qin, Silvia Menéndez, Oriol Arpí-Llucià, Sara García-Alonso, Anna Hernández-Prat, David Casadevall
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::367d536375661e6114b195b210a0e834
https://doi.org/10.1158/1541-7786.22527555.v1
https://doi.org/10.1158/1541-7786.22527555.v1
Autor:
Joaquín Arribas, Cristina Saura, Javier Cortés, Wim H.A. Dokter, Fred A. Dijcks, Verónica Rodilla, Anna Esteve-Codina, Atanasio Pandiella, Lucía Gandullo-Sánchez, Santiago Escrivá-de-Romaní, Sandra Pérez-Ramos, Marta Escorihuela, Beatriz Morancho, Cristina Bernadó Morales, Enrique Javier Arenas, Marta Lalinde-Gutiérrez, Mercedes Nadal-Serrano, Santiago Duro-Sánchez
Effect of doxorubicin and Cdk4/6i on cells expressing different levels of HER2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8318d5a3d9756e26e2f4f168b7743465
https://doi.org/10.1158/0008-5472.22432560
https://doi.org/10.1158/0008-5472.22432560
Autor:
Joaquín Arribas, Cristina Saura, Javier Cortés, Wim H.A. Dokter, Fred A. Dijcks, Verónica Rodilla, Anna Esteve-Codina, Atanasio Pandiella, Lucía Gandullo-Sánchez, Santiago Escrivá-de-Romaní, Sandra Pérez-Ramos, Marta Escorihuela, Beatriz Morancho, Cristina Bernadó Morales, Enrique Javier Arenas, Marta Lalinde-Gutiérrez, Mercedes Nadal-Serrano, Santiago Duro-Sánchez
Antibody–drug conjugates (ADC) are antineoplastic agents recently introduced into the antitumor arsenal. T-DM1, a trastuzumab-based ADC that relies on lysosomal processing to release the payload, is approved for HER2-positive breast cancer. Next-ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0cd93ffd70867fcd1f27692db14b949
https://doi.org/10.1158/0008-5472.c.6514164
https://doi.org/10.1158/0008-5472.c.6514164
Autor:
Joaquín Arribas, Cristina Saura, Javier Cortés, Wim H.A. Dokter, Fred A. Dijcks, Verónica Rodilla, Anna Esteve-Codina, Atanasio Pandiella, Lucía Gandullo-Sánchez, Santiago Escrivá-de-Romaní, Sandra Pérez-Ramos, Marta Escorihuela, Beatriz Morancho, Cristina Bernadó Morales, Enrique Javier Arenas, Marta Lalinde-Gutiérrez, Mercedes Nadal-Serrano, Santiago Duro-Sánchez
Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a498c31e3cd4f923e7ee74e3c1fdda92
https://doi.org/10.1158/0008-5472.22432542.v1
https://doi.org/10.1158/0008-5472.22432542.v1
Autor:
Joaquín Arribas, Cristina Saura, Javier Cortés, Wim H.A. Dokter, Fred A. Dijcks, Verónica Rodilla, Anna Esteve-Codina, Atanasio Pandiella, Lucía Gandullo-Sánchez, Santiago Escrivá-de-Romaní, Sandra Pérez-Ramos, Marta Escorihuela, Beatriz Morancho, Cristina Bernadó Morales, Enrique Javier Arenas, Marta Lalinde-Gutiérrez, Mercedes Nadal-Serrano, Santiago Duro-Sánchez
Extended Materials and Methods and Supplementary figures with legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ab2ec453691e74e2206125dfa522618
https://doi.org/10.1158/0008-5472.22432545
https://doi.org/10.1158/0008-5472.22432545
Autor:
David Casadevall, Anna Hernández-Prat, Sara García-Alonso, Oriol Arpí-Llucià, Silvia Menéndez, Mengjuan Qin, Cristina Guardia, Beatriz Morancho, Francisco Javier Sánchez-Martín, Sandra Zazo, Elena Gavilán, Mohammad A. Sabbaghi, Pilar Eroles, Juan Miguel Cejalvo, Ana Lluch, Federico Rojo, Atanasio Pandiella, Ana Rovira, Joan Albanell
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
In patients with trastuzumab-resistant HER2-positive breast cancer, the combination of everolimus (mTORC1 inhibitor) with trastuzumab failed to show a clinically significant benefit. However, the combination of mTOR inhibition and the antibody-drug c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3656e1cb422ad1d2aa23e9ba81826192
http://hdl.handle.net/10261/282954
http://hdl.handle.net/10261/282954
Autor:
Alex Martínez-Sabadell, Beatriz Morancho, Irene Rius Ruiz, Macarena Román Alonso, Pablo Ovejero Romero, Marta Escorihuela, Irene Chicote, Hector G. Palmer, Lara Nonell, Mercè Alemany-Chavarria, Christian Klein, Marina Bacac, Joaquín Arribas, Enrique J. Arenas
Publikováno v:
Scientia
Cancer; Antigen; Resistance Cáncer; Antígeno; Resistencia Càncer; Antigen; Resistència Despite the revolution of immunotherapy in cancer treatment, patients eventually progress due to the emergence of resistance. In this scenario, the selection o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc127f0012885156478e5e44597d762d
https://pubmed.ncbi.nlm.nih.gov/36261015
https://pubmed.ncbi.nlm.nih.gov/36261015
Autor:
Alex Martínez-Sabadell, Beatriz Morancho, Irene Rius, Marta Escorihuela, Antonio Luque, Irene Chicote, Hector García Palmer, Marina Bacac, Joaquin Arribas, Enrique Javier Arenas Lahuerta
Publikováno v:
Cancer Research. 82:2044-2044
Introduction: Immunotherapy has revolutionized the way many cancers are treated. Despite its success, cancer patients eventually progress due to the emergence of resistance. In this scenario, the selection of the tumor antigen is important and can be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6081361b2faba0e4566dacff503bb5fc
https://doi.org/10.1158/1538-7445.am2022-2044
https://doi.org/10.1158/1538-7445.am2022-2044